NASDAQ:INTS Intensity Therapeutics (INTS) Stock Price, News & Analysis $4.11 +0.23 (+5.93%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$4.10 -0.01 (-0.24%) As of 09/18/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Intensity Therapeutics Stock (NASDAQ:INTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intensity Therapeutics alerts:Sign Up Key Stats Today's Range$3.79▼$4.2950-Day Range$3.81▼$4.9252-Week Range$3.51▼$43.50Volume45,148 shsAverage Volume26,153 shsMarket Capitalization$13.40 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors. Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors. The treatment is being evaluated in clinical studies involving patients with advanced solid tumors, both as a standalone therapy and in combination with other immunotherapies. Intensity Therapeutics was founded in 2012 and is based in the United States. The company has focused on developing therapies for cancers that may be difficult to treat with conventional systemic approaches. Its programs remain investigational and are subject to clinical development and regulatory review. Lewis H. Berman has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Intensity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 262nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingIntensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialIntensity Therapeutics has a consensus price target of $7.00, representing about 70.3% upside from its current price of $4.11.Amount of Analyst CoverageIntensity Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Intensity Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics are expected to grow in the coming year, from ($2.64) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intensity Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intensity Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntensity Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Intensity Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.62% of the float of Intensity Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics has a short interest ratio ("days to cover") of 1.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics has recently decreased by 40.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics does not currently pay a dividend.Dividend GrowthIntensity Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for INTS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Intensity Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Intensity Therapeutics is held by insiders.Percentage Held by Institutions3.74% of the stock of Intensity Therapeutics is held by institutions.Read more about Intensity Therapeutics' insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INTS Stock News HeadlinesBrokerages Set Intensity Therapeutics Inc. (NASDAQ:INTS) PT at $7.00September 10, 2026 | americanbankingnews.comIntensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | prnewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 19 at 1:00 AM | Porter & Company (Ad)Intensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug ResumeSeptember 4, 2026 | rttnews.comIntensity Therapeutics (INTS) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | finance.yahoo.comIntensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3August 11, 2026 | seekingalpha.comIntensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | seekingalpha.comIntensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 11, 2026 | prnewswire.comSee More Headlines INTS Stock Analysis - Frequently Asked Questions How have INTS shares performed this year? Intensity Therapeutics' stock was trading at $10.05 on January 1st, 2026. Since then, INTS stock has decreased by 59.1% and is now trading at $4.11. How were Intensity Therapeutics' earnings last quarter? Intensity Therapeutics Inc. (NASDAQ:INTS) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.24. Read the conference call transcript. When did Intensity Therapeutics' stock split? Shares of Intensity Therapeutics reverse split on the morning of Thursday, February 19th 2026.The 1-25 reverse split was announced on Friday, February 13th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 18th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Intensity Therapeutics IPO? Intensity Therapeutics (INTS) raised $18 million in an initial public offering (IPO) on Friday, June 30th 2023. The company issued 3,900,000 shares at $4.00-$5.00 per share. How do I buy shares of Intensity Therapeutics? Shares of INTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intensity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings8/11/2026Today9/19/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 INTS's financial health is in the Red zone, according to TradeSmith. INTS has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:INTS CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Price Target for Intensity Therapeutics$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+70.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-116.61% Return on Assets-94.01% Debt Debt-to-Equity Ratio0.01 Current Ratio5.00 Quick Ratio5.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book0.83Miscellaneous Outstanding Shares3,260,000Free Float3,017,000Market Cap$13.40 million OptionableNot Optionable Beta2.76 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:INTS) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INTS Stock Alerts